title: Molecular pathways: induction of polyploidy as a novel differentiation therapy for leukemia.
abstract: Differentiation therapy has emerged as a powerful way to target specific hematologic malignancies. One of the best examples is the use of all-trans retinoic acid (ATRA) in acute promyelocytic leukemia (APL), which has significantly improved the outcome for patients with this specific form of acute myeloid leukemia (AML). In considering how differentiation therapy could be used in other forms of AML, we predicted that compounds that induce terminal differentiation of megakaryocytes would be effective therapies for the megakaryocytic form of AML, named acute megakaryocytic leukemia (AMKL). We also speculated that such agents would reduce the burden of abnormal hematopoietic cells in primary myelofibrosis and alter the differentiation of megakaryocytes in myelodysplastic syndromes. Using a high-throughput chemical screening approach, we identified small molecules that promoted many features of terminal megakaryocyte differentiation, including the induction of polyploidization, the process by which cells accumulate DNA to 32N or greater. As the induction of polyploidization is an irreversible process, cells that enter this form of the cell cycle do not divide again. Thus, this would be an effective way to reduce the tumor burden. Clinical studies with polyploidy inducers, such as aurora kinase A inhibitors, are under way for a wide variety of malignancies, whereas trials specifically for AMKL and PMF are in development. This novel form of differentiation therapy may be clinically available in the not-too-distant future. Clin Cancer Res; 19(22); 6084-8. ©2013 AACR.
authors: Authors' Affiliations: Department of Laboratory Medicine, Yale Stem Cell Center, Yale University, New Haven, Connecticut; and Division of Hematology/Oncology, Northwestern University, Chicago, Illinois.
authors: Diane S
authors: DS
authors: Krause
authors: John D
authors: JD
authors: Crispino
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D064096:Aurora Kinase A / Q000037:antagonists & inhibitors; D001381:Azepines / Q000627:therapeutic use; D002454:Cell Differentiation / Q000187:drug effects; D045744:Cell Line, Tumor; D006801:Humans; D007947:Leukemia, Megakaryoblastic, Acute / Q000188:drug therapy* / Q000235:genetics; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000235:genetics; D008533:Megakaryocytes / Q000166:cytology / Q000378:metabolism; D008938:Mitosis / Q000187:drug effects* / Q000235:genetics; D011123:Polyploidy; D055728:Primary Myelofibrosis / Q000188:drug therapy* / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D014212:Tretinoin / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001381:Azepines; C550258:MLN 8237; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D014212:Tretinoin; C576917:AURKA protein, human; D064096:Aurora Kinase A
references: Clin Cancer Res. 2011 Dec 15;17(24):7614-24
references: 22016509
references: Blood. 2005 May 15;105(10):3875-8
references: 15677565
references: Proc Natl Acad Sci U S A. 2001 May 8;98(10):5776-9
references: 11344311
references: J Exp Med. 2012 Oct 22;209(11):2017-31
references: 23045605
references: Blood. 1992 Jun 15;79(12):3325-30
references: 1596573
references: Nat Rev Mol Cell Biol. 2005 Feb;6(2):167-80
references: 15688002
references: Blood. 1999 May 15;93(10):3167-215
references: 10233871
references: Nat Genet. 2001 Jul;28(3):220-1
references: 11431691
references: Blood. 2000 Oct 1;96(7):2405-11
references: 11001891
references: J Cell Biol. 2005 Jul 4;170(1):91-101
references: 15998801
references: Blood. 2010 Jun 24;115(25):5202-13
references: 20382844
references: Oncogene. 2000 Dec 7;19(52):6059-64
references: 11146558
references: Cell Cycle. 2006 Mar;5(5):538-45
references: 16552179
references: Leukemia. 2013 Mar;27(3):731-4
references: 22918081
references: Dev Cell. 2007 May;12(5):713-25
references: 17488623
references: J Cell Biol. 2005 Aug 15;170(4):571-82
references: 16103226
references: Blood. 2003 Jan 15;101(2):541-4
references: 12393414
references: Pediatr Blood Cancer. 2007 Jul;49(1):17-22
references: 16856158
references: Cancer. 2012 Oct 1;118(19):4806-14
references: 22392565
references: Cancer Cell. 2012 Nov 13;22(5):683-97
references: 23153540
references: Leukemia. 2002 Sep;16(9):1622-6
references: 12200673
references: J Cell Biol. 1998 Nov 30;143(5):1249-58
references: 9832553
references: Blood. 2008 Oct 15;112(8):3164-74
references: 18684864
references: Curr Biol. 2002 Oct 29;12(21):1864-70
references: 12419188
references: Leukemia. 2013 Dec;27(12):2280-8
references: 23531517
references: Mol Cancer Ther. 2012 Mar;11(3):763-74
references: 22302096
references: Nature. 2002 Dec 12;420(6916):629-35
references: 12478284
references: Cell. 2012 Aug 3;150(3):575-89
references: 22863010
references: Dev Cell. 2007 May;12(5):699-712
references: 17488622
references: Blood. 2001 Jun 15;97(12):3727-32
references: 11389009
references: Cell Cycle. 2008 Aug;7(15):2352-6
references: 18677109
references: Pediatr Hematol Oncol. 1987;4(3):211-30
references: 2978961
references: Cell Cycle. 2007 Feb 15;6(4):455-60
references: 17312391
references: Curr Opin Hematol. 2007 Sep;14(5):419-26
references: 17934346
references: Nature. 1998 Jul 30;394(6692):491-4
references: 9697773
references: PLoS One. 2010 Nov 29;5(11):e14082
references: 21124766
references: J Clin Oncol. 2008 Jan 20;26(3):414-20
references: 18202418
references: Cell Cycle. 2010 Jul 1;9(13):2589-99
references: 20647776
references: Leukemia. 2009 May;23(5):852-5
references: 19194467
references: Blood. 2008 Nov 15;112(10):4220-6
references: 18755984
references: Curr Opin Cell Biol. 2006 Apr;18(2):199-205
references: 16487696
references: Oncogene. 1999 Apr 29;18(17):2783-8
references: 10348354
references: Nat Genet. 2002 Sep;32(1):148-52
references: 12172547
references: Cancer Cell. 2006 Jul;10(1):65-75
references: 16843266
references: Br J Haematol. 2000 Sep;110(3):512-24
references: 10997960
references: Blood. 2007 Apr 15;109(8):3225-34
references: 17170127
references: Adv Enzyme Regul. 2010;50(1):190-200
references: 19896966